EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Functional and Safety Profile of Limosilactobacillus vaginalis and Development of Oral Fast-Disintegrating Tablets for Gut Microbiota Modulation

Barbara Giordani iD, Federica Monti iD, Elisa Corazza, Sofia Gasperini iD, Carola Parolin iD, Angela Abruzzo, Claudio Foschi iD, Antonella Marangoni iD, Monia Lenzi, Barbara Luppi, Beatrice Vitali iD

Pharmaceutics · 01.08.2025 · 17 (8) · 1011

DOI: 10.3390/pharmaceutics17081011 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmaceutics, online erschienen am 01.08.2025. Verfasst von Barbara Giordani und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy and Biotechnology, Alma Mater Studiorum, University of Bologna, 40127 Bologna, Italy. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 91 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: This work was supported by the Recovery and Resilience Plan, Mission 1 - Component 2 -Investment 6 - NextGenerationEU - AlmaValue for RR - PoC for the valoriza…, NextGenerationEU.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: Early gut colonization by bifidobacteria, occurring more favorably in vaginally born infants than in those delivered via C-section, is crucial for maintaining overall health. The study investigated the health-promoting properties of Limosilactobacillus vaginalis BC17 both as viable cells and as postbiotics (i.e., cell-free supernatant and heat-killed cells), with the purpose of developing oral formulations to support intestinal health.

Methods

The safety, effects on the adhesion of bifidobacteria and enteropathogens to intestinal cells, and anti-inflammatory properties of L. vaginalis BC17 viable cells and postbiotics were evaluated. Fast-disintegrating tablets were formulated by freeze-drying cell-free supernatant in combination with heat-killed or viable cells alongside maltodextrins.

Results

The formulations were shown to be non-genotoxic and compatible with intestinal cell lines (Caco-2 and HT-29). BC17 viable cells survived in co-culture with intestinal cells up to 48 h and exhibited moderate adhesion to the cell lines. Notably, both BC17 viable cells and postbiotics enhanced the adhesion of beneficial bifidobacteria to Caco-2 cells by up to 250%, while reducing enteropathogens adhesion by 40–70%. Moreover, they exerted significant anti-inflammatory effects, reducing nitric oxide production in macrophages by 40–50% and protecting intestinal cells from SDS-induced damage. The formulations allowed administration of at least 109 BC17 cells in infants and adults through easy and rapid dispersion in milk or water, or directly in the oral cavity without chewing, and preserved their functional properties for up to 3 months of storage.

Conclusions

L. vaginalis BC17 viable cells and postbiotics, as well as fast-disintegrating tablets, showed promising functional and safety profiles. Although further in vivo validation is needed, this approach represents a compelling strategy for promoting gut health.

Schlagwörter

Stichwörter der Autor:innen

Limosilactobacillus vaginalisbifidobacteriafast-disintegrating formulationsfreeze-dried tabletsgut healthpostbioticsprobiotics

Autor:innen und Institutionen

  • Department of Pharmacy and Biotechnology, Alma Mater Studiorum, University of Bologna, 40127 Bologna, Italy.
  • Section of Microbiology, Department of Medical and Surgical Sciences, Alma Mater Studiorum, University of Bologna, 40127 Bologna, Italy.
  • Microbiology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy.

ORCID-Profile: Barbara Giordani, Federica Monti, Sofia Gasperini, Carola Parolin, Claudio Foschi, Antonella Marangoni, Beatrice Vitali

Förderung

  • This work was supported by the Recovery and Resilience Plan, Mission 1 - Component 2 -Investment 6 - NextGenerationEU - AlmaValue for RR - PoC for the valoriza…
  • NextGenerationEU

Zitieren

APA

Giordani, B., Monti, F., Corazza, E., Gasperini, S., Parolin, C., Abruzzo, A., Foschi, C., Marangoni, A., Lenzi, M., Luppi, B., & Vitali, B. (2025). Functional and Safety Profile of Limosilactobacillus vaginalis and Development of Oral Fast-Disintegrating Tablets for Gut Microbiota Modulation. Pharmaceutics, 17(8), 1011. https://doi.org/10.3390/pharmaceutics17081011

Vancouver

Giordani B, Monti F, Corazza E, Gasperini S, Parolin C, Abruzzo A, et al. Functional and Safety Profile of Limosilactobacillus vaginalis and Development of Oral Fast-Disintegrating Tablets for Gut Microbiota Modulation. Pharmaceutics. 2025;17(8):1011. doi:10.3390/pharmaceutics17081011

BibTeX
@article{Giordani2025,
  author = {Giordani, Barbara and Monti, Federica and Corazza, Elisa and Gasperini, Sofia and Parolin, Carola and Abruzzo, Angela and Foschi, Claudio and Marangoni, Antonella and Lenzi, Monia and Luppi, Barbara and Vitali, Beatrice},
  title = {Functional and Safety Profile of Limosilactobacillus vaginalis and Development of Oral Fast-Disintegrating Tablets for Gut Microbiota Modulation},
  journal = {Pharmaceutics},
  year = {2025},
  volume = {17},
  number = {8},
  pages = {1011},
  doi = {10.3390/pharmaceutics17081011}
}
Kostenlos starten →